Genetic marker studies assessing individual backgrounds from specific populations can provide information on gene flow, evolutionary history, and population dispersions, and can also help in the prediction of risks for particular diseases. Based on these studies, pharmacogenetic data have shown significant inter- and intra-population differences in the metabolism, efficiencies, and toxicities of several types of drugs. These findings have important implications for the management and treatment of human diseases ([@KittlesandWeiss2003]).

Many different enzyme families are involved in xenobiotic metabolism, including cytochrome P450 (CYPs) in phase I, as well as glutathione S-transferases (GSTs) and N-acetyl-transferases (NATs) in phase II ([@Autrup2000]). Several genes of the CYP family have been studied in many populations (*e.g.*, Europeans, Africans, Asians, and their mixed descendants) in case-control studies of complex diseases. With regard to cancers, these studies focus primarily on lung, breast, and head and neck tumors ([@Olshanetal2000]; [@Gajeckaetal2005]; [@Yangetal2005]; [@Leichsenringetal2006]; [@Losi-Guembarovskietal2008]; [@Torresanetal2008]; [@Varela-Lemaetal2008]).

Variants of GSTs enzymes have been extensively studied and were found to be associated with several types of neoplasias in different populations, such as Europeans and Euro-descendants ([@Parketal2000]; [@GeislerandOlshan2001]; [@Raimondietal2005]; [@Leichsenringetal2006]; [@Losi-Guembarovskietal2008]; [@Torresanetal2008]), Africans and Afro-descendants ([@Dandaraetal2002]; [@Enokidaetal2005]), and Asians ([@Yangetal2005]). Other studies involving genes of xenobiotic metabolism have been performed in order to describe the frequency of the mutant alleles and genotypes in different healthy populations ([@Garteetal2001]; [@Gasparetal2002]; [@Menoyoetal2006]). Some studies carried out in the Brazilian population described mutant allele and genotype frequencies in several regions ([@Arrudaetal1998]; Gattás and Soares Viera, 2000; [@Gasparetal2002]; [@Losi-Guembarovskietal2002]; [@Rossinietal2002]; [@Amorimetal2004]; Gattás *et al.*, 2004; [@Hatagimaetal2004]; [@Kvitkoetal2006]; [@Rossinietal2006]).

In the present report, two distinct groups (Euro-descendants and Afro-descendants) from Curitiba in the South of Brazil were analyzed in order to describe the frequency of six metabolic genes (*CYP1A1,CYP2E1*, *CYP2D6*, *GSTM1*, *GSTT1*, and *GSTP1*). The group of Euro-descendants was comprised of 115 healthy individuals (49 males and 66 females) with an average age of 42.6 ± 7.3 years. The group of Afro-descendants was comprised of 196 healthy individuals (123 males and 73 females) with an average age of 33.4 ± 8.6 years. The ethnic differentiation from these groups was determined through a survey with self-declared information from the individuals that was attached to the Informed Consent agreement. The blood samples were collected in the Hematology and Hemotherapy Center of Paraná State (HEMEPAR), a center for blood donation, by the staff of the Immunogenetics and Histocompatibility Laboratory (LIGH). Genomic DNA was isolated from peripheral white blood cells from all individuals and sampled by a salting out procedure (Bignon and Fernandez-Viña, 1997). Polymerase chain reaction (PCR) primers were designed according to the Genome Data Bank. The genotyping of *CYP1A1\*2A*, *CYP2D6\*4*, *CYP2E1\*5B*, and *GSTP1\*B* was performed by PCR RFLP according to the following protocols, respectively: [@Carstensenetal1993], [@Sobtiaetal2005], [@Katoetal1992], and [@Harriesetal1997]. *GSTM1\*0* and *GSTT1\*0* genotyping was performed by PCR multiplex according to the protocol described by [@Abdel-Rahmanetal1996].

The allele frequencies of the *CYP1A1\*2A, CYP2D6\*4, CYP2E\*5B, GSTP1\*B* and the null genotypes *GSTM1\*0* and *GSTT1\*0* were obtained by direct counting. The Chi-square test was used to: 1) compare the frequencies of dominant and recessive genotypes of the genes *GSTM1\*0* and *GSTT1\*0* in individuals of the Euro and Afro-descendant groups, 2) verify whether the genes *CYP1A1\*2A*, *CYP2D6\*4*, *CYP2E\*5B*, and *GSTP1\*B* were in Hardy-Weinberg equilibrium (HWE), and 3) compare the frequencies of the mutant allele of these genes and the genotypes GSTM1\*0 and GSTT1\*0 with published data. The frequencies of *CYP1A1\*2A*, *CYP2D6\*4*, *CYP2E\*5B*, and *GSTP1\*B,* genotyped in 311 unrelated persons (622 chromosomes) in both samples, were compared via the analysis of the molecular variance (ARLEQUIN 3.1) according to [@Excoffieretal1992]. The fixation index (Fst) was estimated for the entire sample.

The two groups studied were in Hardy-Weinberg equilibrium with regard to genotype frequencies of the genes *CYP1A1\*2A, CYP2D6\*4, CYP2E\*5B* and *GSTP1\*B.* The mutant allele and null genotype frequencies found in the present study were compared with others described in the literature from both non-Brazilian and Brazilian populations (data presented in Tables [1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}). When our data were compared with literature data from non-Brazilian Afro-descendants, the frequencies of individuals with mutant alleles for the genes *CYP2D6\*4*, *GSTP1\*B* and null genotype *GSTM1\*0* were not homogeneously distributed between the populations of this study ([Table 1](#t1){ref-type="table"}). We believe that this discrepancy is due to the different methods used for the classification of ethnic origin among research groups, in spite of the parental population from North and South America may have different gene frequencies. In this sense is important to notice that the partial χ^2^ values from our sample were the main responsible for the observed significance. On the other hand, the frequencies of individuals with mutant alleles and null genotypes (GSTM1\*0 and GSTT1\*0) for the genes studied were homogeneously distributed between populations when the non-Brazilian Europeans and Euro-descendants were considered ([Table 1](#t1){ref-type="table"}). The frequencies of individuals with mutant alleles and null genotypes in Brazil, both for Afro-and Euro-descendants were homogeneously distributed ([Table 2](#t2){ref-type="table"}).

In the comparison of our groups we noticed that there was a homogeneous distribution of the frequency of the genotypes *GSTM1\*0* and *GSTT1\*0* between the Afro-descendants and Euro-descendants; the differences of the frequencies of individuals with dominant and recessive genotypes, respectively, were statistically not significant (χ^2^~1~ = 2.52; p ± 0.10 and χ^2^~1~ = 1.97; p \> 0.10). The analysis of molecular variance (AMOVA) for the genes *CYP1A1\*2A*, *CYP2D6\*4*, *CYP2E1\*5B*, and *GSTP1\*B* showed that 97.47% of the component of genetic variance is present within the ethnic groups and 2.53% (p \< 10^-4^) between them. This lower value justify the lower value of the fixation index or co-ancestry coefficient (Fst = 0.02508 and 0.02565 for Afro- and Euro-descendants, respectively, and 0.02529 for the entire group) observed in this study. F~st,~ is computed as a measure of the population division effect and values up to 0.05 indicate negligible genetic differentiation ([@Adeyemoetal2005]).

Biometabolism genes have been widely used in association studies, and they have contributed to the improvement in understanding the genetic basis of quantitative features (*e.g.*, susceptibility to complex diseases and drug response). Such studies must consider the impact of the population stratification and miscegenation degree of the control population ([@Ardlieetal2002]; [@Freedmanetal2004]) in order to prevent false associations ([@Zembrzuskietal2006]). When genes with ethnic variation frequencies are evaluated in association studies (especially in complex diseases with multiple environmental and genetic factors), the high-risk group may present a low prevalence of the high-risk allele if other genetic or environmental risk factors predominate in that group ([@ZivandBurchard2003]).

The present report provides data that can contribute to the general profile of frequency and population dynamics of biometabolizing genes in groups of the Southern Brazilian population. These data constitute a valuable resource for the planning of future association studies in complex diseases like cancers.
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###### 

Comparison between the present data and frequencies obtained in non-Brazilian samples.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Genes          Frequencies     n       Reference (population)                                    Frequencies     n       Reference (population)
  -------------- --------------- ------- ------------------------------------------------------ -- --------------- ------- ---------------------------------------------------------------
  *CYP1A1\*2A*   0.210\          389\    [@LeMarchandetal1998] (Hawaii and California - USA)\      0.094\          4453\   [@Garteetal2001] (Europeans - GSEC\*)\
                 0.239\          461\    [@Garteetal2001] (Africans - GSEC\*)\                     0.104\          453\    [@Hungetal2003] (Europeans and Euro - Americans)\
                 0.235\          550\    [@Wrenschetal2005] (San Francisco - USA)\                 0.092\          419\    [@Taiolietal2003] (Europeans and Euro - descendants (GSEC\*)\
                 0.301 ± 0.310   196     Present study\                                            0.104\          520\    [@Raimondietal2005] (Europeans - GSEC\*)\
                                         χ^2^~3~ = 6.07; p \> 0.10                                 0.106\          146\    [@Wenzlaffetal2005] (Detroit - USA)\
                                                                                                   0.152 ± 0.279   115     Present study\
                                                                                                                           χ^2^~5~ = 5.32; p \> 0.10

                                                                                                                           

  *CYP2D6\*4*    0.071\          246\    [@Leathartetal1998] (Los Angeles - USA)\                  0.197\          211\    [@Longuemauxetal1999] (France)\
                 0.070\          386\    [@Huangetal1999] (Ghana)\                                 0.180\          408\    [@Gaedigketal2002] (Atlanta - USA)\
                 0.078\          308\    [@Wanetal2001] (Souhern California - USA)\                0.153\          360\    [@Scordoetal2004] (Italy)\
                 0.054\          502\    [@Gaedigketal2002] (Atlanta - USA)\                       0.202\          305\    [@Gajeckaetal2005] (Poland)\
                 0.145 ± 0.263   196     Present study\                                            0.138\          105\    [@Menoyoetal2006] (Spain)\
                                         χ^2^~4~ = 16.98;p \< 0.01                                 0.215 ± 0.249   114     Present study\
                                                                                                                           χ^2^~5~ = 5.34; p \> 0.30

                                                                                                                           

  *CYP2E1\*5B*   0.070\          114l\   [@Wuetal1997] (Texas - USA)\                              0.037\          1454\   [@Garteetal2001] (Europeans - GSEC\*)\
                 0.079 ± 0.197   196     Present study\                                            0.028\          323\    [@Gajeckaetal2005] (Poland)\
                                         χ^2^~1~ = 0.086; p \> 0.70                                0.050 ± 0.152   109     Present study\
                                                                                                                           χ^2^~2~ = 1.36; p \> 0.50

                                                                                                                           

  *GSTM1\*0*     0.200\          120\    [@Fordetal2000] (Columbia and New York - USA)\            0.452\          168\    [@Olshanetal2000] (North Carolina - USA)\
                 0.278\          259\    [@Millikanetal2000] (North Carolina - USA)\               0.520\          369\    [@Millikanetal2000] (North Carolina - USA)\
                 0.267\          479\    [@Garteetal2001] (Africans - GSEC\*)\                     0.542\          395\    [@Gudmundsdottiretal2001] (Iceland)\
                 0.330\          114\    [@Dandaraetal2002] (Tanzania)\                            0.500\          1282\   [@Taiolietal2003] (GSEC\*)\
                 0.368 ± 0.480   190     Present study\                                            0.513\          1981\   [@Raimondietal2005] (GSEC\*)\
                                         χ^2^~4~ = 13.03; p \< 0.05                                0.461 ± 0.500   115     Present study\
                                                                                                                           χ^2^~5~ = 5.78; p \> 0.30

                                                                                                                           

  *GSTT1\*0*     0.166\          259\    [@Millikanetal2000] (North Carolina - USA)\               0.130\          168\    [@Olshanetal2000] (North Carolina - USA)\
                 0.250\          114\    [@Dandaraetal2002] (Tanzania)\                            0.164\          373\    [@Millikanetal2000] (North Carolina - USA)\
                 0.242 ± 0.424   €190    Present study\                                            0.132\          478\    [@Mitrunenetal2001] (Finnish)\
                                         χ^2^~2~ = 5.55; p \> 0.05                                 0.174 ± 0.381   115     Present study\
                                                                                                                           χ^2^~3~ = 3.01; p \> 0.30

                                                                                                                           

  *GSTP1\*B*     0.508\          247\    [@Millikanetal2000] (North Carolina - USA)\               0.310\          189\    [@Longuemauxetal1999] (France)\
                 0.378 ± 0.332   196     Present study\                                            0.306\          368\    [@Millikanetal2000] (North Carolina - USA)\
                                         χ^2^~1~ = 7.53; p \< 0.01                                 0.288\          1138\   [@Garteetal2001] (Europeans - GSEC\*)\
                                                                                                   0.259\          481\    [@Mitrunenetal2001] (Finnish)\
                                                                                                   0.291\          153\    [@Dufouretal2005] (Italy)\
                                                                                                   0.283 ± 0.339   115     Present study\
                                                                                                                           χ^2^~5~ = 2.99; p \> 0.70
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

n = number of individuals; \*GSEC - Genetic Susceptibility to Environmental Carcinogens Database.

###### 

Comparison between the present data and frequencies obtained in other Brazilian samples

  -----------------------------------------------------------------------------------------------------------------------------------------
  Genes           Frequencies     n      Authors (Brazilian region)             Frequencies      n      Authors (Brazilian region)
  --------------- --------------- ------ ----------------------------------- -- ---------------- ------ -----------------------------------
  *CYP1A1\*2A*    0.305\          100\   [@Kvitkoetal2006] (South)\             0.106\           85\    [@Torresanetal2008] (South)\
                  0.301 ± 0.310   196    Present study\                         0.173\           90\    [@Kvitkoetal2006] (South)\
                                         χ^2^~1~ = 0.005;p \> 0.90              0.152 ± 0.279    115    Present study\
                                                                                                        χ^2^~2~ = 1.64; p \> 0.30

                                                                                                        

  *CYP2E1\*5B*    0.029\          136\   Gattás *et al.* 2000 (Southeast)\      0.069\           151\   [@Rossinietal2006] (Southeast)\
                  0.058\          86\    [@Rossinietal2006] (Southeast)\        0.061\           66\    [@Torresanetal2008] (South)\
                  0.079 ± 0.197   196    Present study\                         0.050 ± 0.152l   109    Present study\
                                         χ^2^~2~ = 3.71;p \> 0.10                                       χ^2^~2~ = 0.40; p \> 0.80

                                                                                                        

  *CYP2D6\*4\**   \-              \-     \-                                     0.188\           85\    [@Torresanetal2008] (South)\
                                                                                0.215 ± 0.249    114    Present study\
                                                                                                        χ^2^~1~ = 0.21; p \> 0.50

                                                                                                        

  *GSTM1\*0*      0.330\          117\   [@Arrudaetal1998] (Northeast)\         0.450\           130\   [@Arrudaetal1998] (Southeast)\
                  0.342\          272\   [@Rossinietal2002] (Southeast)\        0.489\           319\   [@Rossinietal2002] (Southeast)\
                  0.328\          137\   Gattás *et al.* 2004 (Southeast)\      0.446\           233\   Gattás *et al.* 2004 (Southeast)\
                  0.340\          100\   [@Kvitkoetal2006] (South)\             0.500\           90\    [@Kvitkoetal2006] (South)\
                  0.368 ± 0.480   190    Present study\                         0.463\           95\    [@Torresanetal2008] (South)\
                                         χ^2^~4~ = 0.72; p \> 0.90              0.461 ± 0.500    115    Present study\
                                                                                                        χ^2^~5~ = 1.65; p \> 0,80

                                                                                                        

  *GSTT1\*0*      0.190\          117\   [@Arrudaetal1998] (Northeast)\         0.185\           130\   [@Arrudaetal1998] (Southeast)\
                  0.257\          272\   [@Rossinietal2002] (Southeast)\        0.215\           319\   [@Rossinietal2002] (Southeast)\
                  0.263\          137\   Gattás *et al.* 2004 (Southeast)\      0.223\           233\   Gattás *et al.* 2004 (Southeast)\
                  0.280\          100\   [@Kvitkoetal2006] (South)\             0.211\           90\    [@Kvitkoetal2006] (South)\
                  0.242 ± 0.424   190    Present study\                         0.295\           95\    [@Torresanetal2008] (South)\
                                         χ^2^~4~ = 3.14; p \> 0.50              0.174 ± 0.381    115    Present study\
                                                                                                        χ^2^~5~ = 5.53; p \> 0,20

                                                                                                        

  *GSTP1\*B*      0.420\          100\   [@Kvitkoetal2006] (South)\             0.315\           319\   [@Rossinietal2002] (Southeast)\
                  0.378 ± 0.332   196    Present study\                         0.278\           90\    [@Kvitkoetal2006] (South)\
                                         χ^2^~1~ = 0.50; p \> 0.30              0.330\           85\    [@Torresanetal2008] (South)\
                                                                                0.283 ± 0.339    115    Present study\
                                                                                                        χ^2^~3~ = 0.99;p \> 0.80
  -----------------------------------------------------------------------------------------------------------------------------------------

n = number of individuals; \* no data to compare.
